x

RSS Newsfeeds

See all RSS Newsfeeds

Jul 16, 2015 10:27 EST

The Diabetic Boot Company: Medical devices aimed at keeping diabetics happy, healthy and whole

iCrowdNewswire - Jul 16, 2015

The Diabetic Boot Company

Investment Summary

This deal will only be listed until 23.59pm on Thursday 30th July as this is the board’s cut off date for investment at this share price.

There were an estimated 382 million people with diabetes worldwide in 2013. Every 20 seconds, somewhere in the world, a diabetic limb is amputated. In 2014, the NHS in England spent £1 in every £150 on the treatment of DFUs and associated lower limb amputation.

CEO Les Lindsay founded The Diabetic Boot Company with the aim of developing innovative biotechnology to answer this growing problem. His previous experience as General Manager of KCI Medical, a $1.3 billion global wound care company, and chairman of the British Healthcare Trades Association provides him with a unique insight into the industry, as well as valuable relationships with key opinion leaders. During his time at KCI, Les grew revenues by over 500% and turned what was a loss-making subsidiary into a profitable one. 

The lead investor in this round is Jim Mellon, well-known early-stage investor, whose best investment success to date was his investment into AIM-listed UraMin Inc, which was listed in 2005 and sold in 2007 to French multinational Areva for approximately £1.6 billion.

You can read more about Jim Mellon in:

This Is Money
The Telegraph
The FT
FT Advisor
The Sunday Times

 

The company has received several awards and grants including:

–        Start Up Business Winner – 2014 SEHTA Healthcare Business Awards

–        Runner up  Start Up Business– 2015 Medilink UK Awards

–        Funding grant from Technology Strategy Board

They have also been featured in the press, both locally and nationally, including an article from The Telegraph.

Around the world, obesity and its co-morbidities are at epidemic levels and rising. The International Diabetes Federation forecasts that the number of diabetics worldwide is likely to reach 552 million by 2030. 

Healthcare providers are deeply concerned about the rising costs of non-healing diabetic foot ulcers; in the UK alone, these wounds cost the NHS £732 million annually. 

To answer this growing demand, the Diabetic Boot Company has developed the Pulse-Flow Pulseboot. This therapeutic device combines well-established practice with innovative technology to encourage healing. It is a patented design which is clinically proven.

Closing on or before

The Diabetic Boot Company closes on midnight Thursday 30th July.

Company Details

The Diabetic Boot Company

Midshires Business Park, Smeaton Close
Aylesbury HP19 8HL

http://www.pulse-flow.co.uk/ 

Contact Information:

Les Lindsay
Nick Hyde
Anthony Chow
Peter Steggles
Tim de Vere Green

View Related News >
support